Table I.
Clinical and pathological responses to neoadjuvant chemotherapy.
| Factors | No. of patients (%) | cCR | P-value | pCR | P-value |
|---|---|---|---|---|---|
| Age (years) | |||||
| ≤50 | 30 (55.6) | 6 (20) | 0.46 | 13 (43) | 0.45 |
| >51 | 24 (44.4) | 3 (13) | 8 (33) | ||
| Stage | |||||
| IIA | 9 (16.7) | 1 (11) | 0.03 | 1 (11) | 0.10 |
| IIB | 31 (57.4) | 3 (10) | 12 (39) | ||
| III | 14 (25.9) | 5 (36) | 8 (57) | ||
| T factor | |||||
| T1 | 3 (5.6) | 2 (67) | 0.16 | 2 (67) | 0.31 |
| T2 | 48 (88.9) | 7 (15) | 18 (38) | ||
| T3 | 3 (5.6) | 0 (0) | 1 (33) | ||
| N factor | |||||
| N0 | 8 (14.8) | 1 (13) | 0.03 | 1 (13) | 0.10 |
| N1 | 32 (59.3) | 3 (9) | 12 (38) | ||
| N2 | 14 (25.9) | 5 (36) | 8 (57) | ||
| Receptor status | |||||
| ER+/PR+ | 24 (44.4) | 3 (13) | 0.36 | 7 (29) | 0.08 |
| ER+/PR− | 9 (16.7) | 1 (11) | 4 (44) | ||
| ER−/PR+ | 4 (7.4) | 1 (25) | 1 (25) | ||
| ER−/PR− | 17 (31.5) | 4 (24) | 9 (53) | ||
| Her2 status | |||||
| Her2+ | 4 (7.4) | 1 (25) | 0.66 | 3 (75) | 0.13 |
| Her2− | 49 (90.7) | 8 (16) | 18 (36) | ||
| Combination | |||||
| HR+/HER2+ | 1 (1.9) | 1 (100) | 1 (100) | ||
| HR+/HER2− | 35 (64.8) | 4 (11) | 10 (29) | ||
| HR−/HER2+ | 3 (5.6) | 0 (0) | 2 (67) | ||
| HR−/HER2− | 15 (27.9) | 4 (27) | 8 (53) | ||
| Total | 54 | 9 (17) | 21 (39) |
cCR, clinical complete response; pCR, pathological complete response. ER, estrogen receptor; PR, progesterone receptor.